CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

Yi-Long Wu,Wen-Zhao Zhong,Qun Wang,Weimin Mao,Song-Tao Xu,Lin Wu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Jin-Ji Yang,Hong-Hong Yan,Xue-Ning Yang,Si-Yang Liu,Qing Zhou

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

2020

Yi-Long Wu
Wen-Zhao Zhong
Qun Wang
Weimin Mao
Song-Tao Xu
Lin Wu
Chun Chen
Ying Cheng
Lin Xu
Jun Wang
Xiaofei Li
Jian Li
Cheng Huang
Zhidong Liu
Shun Xu
Jin-Ji Yang
Hong-Hong Yan
Xue-Ning Yang
Si-Yang Liu
Qing Zhou

9005Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet chemotherapy in patients (p...

Keywords:

Adjuvant
egfr mutation
Oncology
Chemotherapy
overall survival
Internal medicine
Pathology
Gefitinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations